| Schedule of Segment Reporting Information, by Segment |
The following table presents certain financial data for the Company’s reportable segment (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended June 30, | | Six months ended June 30, | | 2026 | | 2025 | | 2026 | | 2025 | | Clinical trial expenses | $ | 1,598 | | | $ | 3,245 | | | $ | 2,779 | | | $ | 7,438 | | | Employee related research and development expenses | 2,763 | | | 2,326 | | | 5,432 | | | 4,623 | | | Chemistry, manufacturing and controls expenses | 1,229 | | | 384 | | | 2,965 | | | 1,030 | | | Other research and development expenses | 1,221 | | | 1,316 | | | 2,392 | | | 2,452 | | | Contract and grant reimbursements | — | | | (265) | | | — | | | (754) | | | Employee related general and administrative expenses | 1,887 | | | 1,362 | | | 3,712 | | | 2,449 | | | Professional fees and other general and administrative expenses | 1,731 | | | 1,723 | | | 3,751 | | | 3,589 | | Other segment items(1) | (2,212) | | | 470 | | | (991) | | | 943 | | | Segment net loss | $ | 8,217 | | | $ | 10,561 | | | $ | 20,040 | | | $ | 21,770 | | | | | | | | | | | | | | | | | |
(1)Other segment items include interest income, interest expense, and change in the fair value of liability-classified warrants. | | | | | | | | | | | | | June 30,
2026 | | December 31,
2025 | | Total segment assets | $ | 31,330 | | | $ | 25,862 | |
|